Glaukos touts Ph2 glaucoma trial for drug-eluting implant

Glaukos (NYSE:GKOS) touted data today from a Phase II trial of its travoprost intraocular implant in a 12-month cohort of glaucoma patients. The company’s iDose device is placed during a micro-invasive procedure and filled with a special formulation of travoprost – a drug used to reduce intraocular pressure. The implant continuously delivers therapeutic levels of travoprost within the eye and when it’s depleted, the iDose is removed and replaced. Get the full story at our sister site, Drug Delivery Business News. The post Glaukos touts Ph2 glaucoma trial for drug-eluting implant appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Glaukos Source Type: news